

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 06D0516830	(X3) Date Survey Completed 06/04/2024
Name of Provider or Supplier Sedgwick County Health Center	Street Address, City, State 900 Cedar St, Julesburg, CO	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a routine desk review of the CMS-155 report for Proficiency Testing (PT) performance and email communications with the laboratory manager, the laboratory failed to achieve satisfactory performance scores for the American Proficiency Institute (API) PT for Cell ID or WBC Diff for two out of three PT events (event 3 in 2023 and event 1 in 2024). See D2121.</p>
D2121	<p>HEMATOLOGY CFR(s): 493.851(a)</p>

Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event.

This STANDARD is not met as evidenced by:

Based on a routine desk review of the CMS-155 report for Proficiency Testing (PT), and email communication with the laboratory manager, the laboratory failed to achieve a satisfactory score for Cell ID or WBC Diff for event 3 in 2023 and event 1 in 2024. Findings: 1. A review of the CMS-155 Individual Laboratory Profile on May 10, 2024, at 01:18 PM, revealed the API PT results for Cell ID or WBC Diff testing scores for event 3 in 2023 was 0%, and 60% for event 1 in 2024. 2. An email with the laboratory's manager on May 13, 2024, at 02:11 PM, confirmed the laboratory failed to achieve satisfactory test performance for Cell ID or WBC Diff.